CARsgen Therapeutics Holdings Limited 2171.HK Stock
CARsgen Therapeutics Holdings Limited Price Chart
CARsgen Therapeutics Holdings Limited 2171.HK Financial and Trading Overview
CARsgen Therapeutics Holdings Limited stock price | 4.77 HKD |
Previous Close | 10.84 HKD |
Open | 10.9 HKD |
Bid | 10.86 HKD x N/A |
Ask | 10.9 HKD x N/A |
Day's Range | 10.62 - 11.22 HKD |
52 Week Range | 9.2 - 21.85 HKD |
Volume | 1.13M HKD |
Avg. Volume | 1.69M HKD |
Market Cap | 6.22B HKD |
Beta (5Y Monthly) | N/A |
PE Ratio (TTM) | N/A |
EPS (TTM) | -1.8 HKD |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 21.62 HKD |
2171.HK Valuation Measures
Enterprise Value | 4.05B HKD |
Trailing P/E | N/A |
Forward P/E | -6 |
PEG Ratio (5 yr expected) | N/A |
Price/Sales (ttm) | N/A |
Price/Book (mrq) | 2.514471 |
Enterprise Value/Revenue | N/A |
Enterprise Value/EBITDA | -5.412 |
Trading Information
CARsgen Therapeutics Holdings Limited Stock Price History
Beta (5Y Monthly) | N/A |
52-Week Change | -11.14% |
S&P500 52-Week Change | 20.43% |
52 Week High | 21.85 HKD |
52 Week Low | 9.2 HKD |
50-Day Moving Average | 11.88 HKD |
200-Day Moving Average | 14.28 HKD |
2171.HK Share Statistics
Avg. Volume (3 month) | 1.69M HKD |
Avg. Daily Volume (10-Days) | 836.1K HKD |
Shares Outstanding | 572.63M |
Float | 343.02M |
Short Ratio | N/A |
% Held by Insiders | 42.06% |
% Held by Institutions | 14.00% |
Shares Short | N/A |
Short % of Float | N/A |
Short % of Shares Outstanding | N/A |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0 |
Last Split Factor |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2022 |
Most Recent Quarter (mrq) | December 31, 2022 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | 0% |
Operating Margin (ttm) | 0% |
Gross Margin | 0% |
EBITDA Margin | 0% |
Management Effectiveness
Return on Assets (ttm) | -16.064% |
Return on Equity (ttm) | -32.62% |
Income Statement
Revenue (ttm) | N/A |
Revenue Per Share (ttm) | N/A |
Quarterly Revenue Growth (yoy) | N/A |
Gross Profit (ttm) | N/A |
EBITDA | -748728000 HKD |
Net Income Avi to Common (ttm) | -892246976 HKD |
Diluted EPS (ttm) | -1.9 |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | 2.27B HKD |
Total Cash Per Share (mrq) | 3.97 HKD |
Total Debt (mrq) | 119.45M HKD |
Total Debt/Equity (mrq) | 4.83 HKD |
Current Ratio (mrq) | 13.454 |
Book Value Per Share (mrq) | 4.319 |
Cash Flow Statement
Operating Cash Flow (ttm) | -643048000 HKD |
Levered Free Cash Flow (ttm) | -500786368 HKD |
Profile of CARsgen Therapeutics Holdings Limited
Country | Hong Kong |
State | N/A |
City | Shanghai |
Address | Building 12 |
ZIP | N/A |
Phone | N/A |
Website | https://www.carsgen.com |
Industry | Biotechnology |
Sector(s) | Healthcare |
Full Time Employees | 539 |
CARsgen Therapeutics Holdings Limited, an investment holding company, engages in discovering, developing, and commercializing chimeric antigen receptor T (CAR-T) cell therapies in China and the U.S. The company is developing autologous CAR-T product candidates, including CT053, which targets B-cell maturation antigen that is in pivotal Phase II/III trial for the treatment of relapsed/refractory multiple myeloma; CT041, which targets Claudin 18.2, is in Phase II/III clinical trial for gastric/gastroesophageal junction cancer and Phase I for pancreatic cancer, as well as in Phase I clinical trial for gastric or pancreatic cancer; and CT011, which is in Phase I clinical trial for patients with Glypican-3 positive advanced hepatocellular carcinoma. It is also developing CT032, which targets CD19 that is in Phase I/II clinical trial for the treatment of B cell non-Hodgkin's lymphoma; CT0180, which targets Glypican-3 that is in Phase I clinical trial for patients with Glypican-3 positive advanced hepatocellular carcinoma; and CT0181, which targets Glypican-3 that is in Phase I clinical trial for patients with Glypican-3 positive hepatocellular carcinoma. In addition, the company is developing CT0590, which targets B-cell maturation antigen that is in pre-clinical stage for the treatment of relapsed/refractory multiple myeloma; CT048, which targets Claudin 18.2 that is in pre-clinical stage for the treatment of gastric/gastroesophageal junction and pancreatic cancer; KJ-C2112, an epidermal growth factor receptor/variant III of epidermal growth factor receptor, which is in pre-clinical stage for the treatment of glioblastoma; and KJC2113 that targets mesothelin, as well as KJ-C2114 that are in pre-clinical stage for the treatment of solid tumors. Further, it is developing AB011, which is in Phase I clinical trial for the treatment of gastric/pancreatic cancer. The company was founded in 2014 and is headquartered in Shanghai, China.
Q&A For CARsgen Therapeutics Holdings Limited Stock
What is a current 2171.HK stock price?
CARsgen Therapeutics Holdings Limited 2171.HK stock price today per share is 4.77 HKD.
How to purchase CARsgen Therapeutics Holdings Limited stock?
You can buy 2171.HK shares on the HKSE exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for CARsgen Therapeutics Holdings Limited?
The stock symbol or ticker of CARsgen Therapeutics Holdings Limited is 2171.HK.
Which industry does the CARsgen Therapeutics Holdings Limited company belong to?
The CARsgen Therapeutics Holdings Limited industry is Biotechnology.
How many shares does CARsgen Therapeutics Holdings Limited have in circulation?
The max supply of CARsgen Therapeutics Holdings Limited shares is 575.35M.
What is CARsgen Therapeutics Holdings Limited Price to Earnings Ratio (PE Ratio)?
CARsgen Therapeutics Holdings Limited PE Ratio is now.
What was CARsgen Therapeutics Holdings Limited earnings per share over the trailing 12 months (TTM)?
CARsgen Therapeutics Holdings Limited EPS is -1.8 HKD over the trailing 12 months.
Which sector does the CARsgen Therapeutics Holdings Limited company belong to?
The CARsgen Therapeutics Holdings Limited sector is Healthcare.
CARsgen Therapeutics Holdings Limited 2171.HK included in indexes
Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
---|
Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
---|---|---|---|---|---|---|---|
{{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
Nasdaq EM Plus Korea Small Cap NQEMKRSCGBP | 1476.35 GBP 1888.16 USD |
<0.01
|
— — | 1476.35 GBP 1888.16 USD | 1476.35 GBP 1888.16 USD | — - | — — |
- {{ link.label }} {{link}}